A multicenter phase II trial of gemcitabine plus oxaliplatin in unresectable gallbladder cancer

Gut and Liver

Volumn 7, Issue 5, 2013, Pages 594-598

  Woo, Sang Myung ^a,b   Lee, Sang Hyub ^a,c   Yoo, Ji Won ^a   Yang, Ki Young ^a   Seo, Jung Gyun ^a   Park, Joo Kyung ^a   Hwang, Jin Hyeok ^c   Lee, Woo Jin ^b   Ryu, Ji Kon ^a   Kim, Yong Tae ^a   Yoon, Yong Bum ^a  

^a Seoul National University Hospital   (South Korea)

^b National Cancer Center   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

Author keywords

Gallbladder neoplasms; Gemcitabine; Oxaliplatin

Indexed keywords

GEMCITABINE; OXALIPLATIN;

ADULT; ANEMIA; ARTICLE; CANCER CONTROL; CHOLANGIOHEPATITIS; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; GALLBLADDER CANCER; HEPATITIS; HUMAN; KOREA; LUNG EMBOLISM; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84884744581     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl.2013.7.5.594     Document Type: Article

References (24)

1. Misra S, Chaturvedi A, Misra NC, Sharma ID. Carcinoma of the gallbladder. Lancet Oncol 2003;4:167-176. (Pubitemid 36322307)
2. Lazcano-Ponce EC, Miquel JF, Muñoz N, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 2001;51:349-364. (Pubitemid 34232782)
3. Shin HR, Jung KW, Won YJ, Park JG; 139 KCCR-affiliated Hospitals. 2002 Annual report of the Korea Central Cancer Registry: based on registered data from 139 hospitals. Cancer Res Treat 2004;36:103-114.
4. Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer 2006;118:1591-1602. (Pubitemid 43376420)
5. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med 1999;341:1368-1378.
6. Glimelius B, Hoffman K, Sjödén PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996;7:593-600. (Pubitemid 26285639)
7. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273-1281.
8. Jarnagin WR, Klimstra DS, Hezel M, et al. Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome. J Clin Oncol 2006;24:1152-1160. (Pubitemid 46638813)
9. Yonemoto N, Furuse J, Okusaka T, et al. A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol 2007;37:843-851. (Pubitemid 350259003)
10. Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007;96:896-902. (Pubitemid 46452283)
11. Kimura K, Ohto M, Saisho H, et al. Association of gallbladder carcinoma and anomalous pancreaticobiliary ductal union. Gastroenterology 1985;89:1258-1265. (Pubitemid 16228046)
12. Park YK, Kim SW, Park YH. A clinical study of gallbladder carcinoma. Korean J Gastroenterol 1989;21:113-122.
13. Hanada K, Itoh M, Fujii K, Tsuchida A, Ooishi H, Kajiyama G. K-ras and p53 mutations in stage I gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Cancer 1996;77:452-458. (Pubitemid 26047565)
14. Andre T, Tournigand C, Rosmorduc O, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 2004;15:1339-1343. (Pubitemid 39295020)
15. Andre T, Reyes-Vidal JM, Fartoux L, et al. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer 2008;99:862-867.
16. Kim HJ, Lee NS, Lee SC, et al. A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer. Cancer Chemother Pharmacol 2009;64:371-377.
17. Sharma A, Mohanti B, Raina V, et al. A phase II study of gemcitabine and oxaliplatin (Oxigem) in unresectable gall bladder cancer. Cancer Chemother Pharmacol 2010;65:497-502.
18. Harder J, Riecken B, Kummer O, et al. Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer 2006;95:848-852. (Pubitemid 44498100)
19. Lee J, Park SH, Chang HM, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2012;13:181-188.
20. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
21. Gallardo JO, Rubio B, Fodor M, et al. A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol 2001;12:1403-1406. (Pubitemid 33100245)
22. Malik IA, Aziz Z, Zaidi SH, Sethuraman G. Gemcitabine and Cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of the gallbladder. Am J Clin Oncol 2003;26:174-177. (Pubitemid 36443562)
23. Doval DC, Sekhon JS, Gupta SK, et al. A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. Br J Cancer 2004;90:1516-1520. (Pubitemid 38648231)
24. Chatni SS, Sainani RS, Mehta SA, Mohandas KM. Infusion chemotherapy with cisplatinum and fluorouracil in the treatment of locally-advanced and metastatic gallbladder cancer. J Cancer Res Ther 2008;4:151-155.